Functional glass-ceramic foams from \u2018inorganic gel casting\u2019 and sintering of glass/slag mixtures

The here described investigation was essentially aimed at exploring the chemical stabilization and reutilization of iron-rich slag from copper metallurgy, by the manufacturing of glass-ceramic foams. The foams were developed according to a new method, recently reported for pure recycled soda-lime glass. Mixtures of soda-lime glass/slag powders (with slag content ranging from 10 to 30\u202fwt%), suspended in alkaline aqueous solution, underwent progressive low temperature (80\u202f\ub0C) hardening, owing to the formation of hydrated calcium silicate compounds (CSH). Before complete setting, an extensive foaming could be achieved by vigorous mechanical stirring, with the help of a surfactant. After foaming, glass/slag mixtures could be sintered at 800\u20131000\u202f\ub0C; the mutual interaction caused an extensive crystallization, with precipitation of CaFe silicates and iron oxides (hematite and magnetite), promoting the mechanical properties (up to 4.4\u202fMPa, with a porosity of about 80%). Leaching test confirmed the stabilization of pollutants, from the slag, in the final ceramics. Owing to the separation of iron oxides, particularly magnetite, the newly obtained foams exhibited a ferrimagnetic behavior, that could be exploited in electromagnetic shielding applications

How patients' experiences help institutions to improve care in oncological pathway.

To improve services, institutions need to listen the patients voice. The patient experience through the health care pathway can help institutions to point out the problems and to learn to design the organization putting the patient at the center of the service. Methods. Focus groups were performed on a group of patients affected by colon rectum neoplasia who had an operation during June-September 2003 in the hospitals located in three geographical districts. It was performed a focus group per district in the period between June and July 2004. Results. Overall patient were interviewed in district A, B and C, respectively. District C included a Universtiy Hospital and a Community Hospital. We choose the focus group technics because of the peculiarity of the studied disease. By a crossed reading of patients' experience we obtained two type of informations: how CORD is working (CORD is the structure which has the role of coordination of oncological pathway, according to the regional guidelines) and which are the strength ness and the weakness of the services delivered by each healthcare unit participating at the study. The patient experience in benchmarking through out different institutions, has been useful for managers to start an internal process of reviewing critical points regarding above all humanization and care coordination along the heath care pathway. Particularly interesting is the case of the University Hospital of Pisa, where the patients indications allowed the institution to reengineering the process, to improve services and empower the communication skills of the physicians and nurses involved in the clinical pathway . Conclusions. Patient point of view in oncological care was an easy tool for improving the health care pathway. It gives to health managers a simple method that allows the organization to evaluate services through the patients eyes .Focus group, Oncological pathway, Patients’ point of view

Mitochondrial Stress Signalling: HTRA2 and Parkinson's Disease

Mitochondria are cellular energy generators whose activity requires a continuous supply of oxygen. Recent genetic analysis has suggested that defects in mitochondrial quality control may be key factors in the development of Parkinson's disease (PD). Mitochondria have a crucial role in supplying energy to the brain, and their deterioration can affect the function and viability of neurons, contributing to neurodegeneration. These organelles can sow the seeds of their own demise because they generate damaging oxygen-free radicals as a byproduct of their intrinsic physiological functions. Mitochondria have therefore evolved specific molecular quality control mechanisms to compensate for the action of damaging agents such as oxygen-free radicals. PTEN-induced putative kinase 1 (PINK1) and high-temperature-regulated A2 (HTRA2), a mitochondrial protease, have recently been proposed to be key modulators of mitochondrial molecular quality control. Here, we review some of the most recent advances in our understanding of mitochondria stress-control pathways, focusing on how signalling by the p38 stress kinase pathway may regulate mitochondrial stress by modulating the activity of HTRA2 via PINK1 and cyclin-dependent kinase 5 (CDK5). We also propose how defects in this pathway may contribute to PD

Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak

Purpose: The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ. Methods: A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020. Results: Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future. Conclusion: A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.

Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME). Despite the important clinical achievements obtained by anti-VEGF drugs in the management of w-AMD and DME; some limits still remain; including high treatment burden; the presence of unsatisfactory results in a certain percentage of patients and long-term visual acuity decline due to complications such as macular atrophy and fibrosis. Targeting the angiopoietin/Tie (Ang/Tie) pathway beyond the VEGF pathway may be a possible therapeutic strategy; which may has the potential to solve some of the previous mentioned challenges. Faricimab is a new; bispecific antibody targeting both VEGF-A and the Ang-Tie/pathway. It was approved by FDA and; more recently; by EMA for treating w-AMD and DME. Results from phase III trials TENAYA and LUCERNE (w-AMD) and RHINE and YOSEMITE (DME) have shown the potential of faricimab to maintain clinical efficacy with more prolonged treatment regimens compared to aflibercept (12 or 16 weeks) with a a good safety profile

Low temperature upcycling of vitreous byproduct of the MSW plasma processing into multifunctional porous glass-ceramics

Mixtures of glass residues, deriving from the plasma processing of municipal solid waste (‘Plasmastone’), and recycled glasses have been already converted into highly porous glassceramics by application of an inorganic gel casting technique (foaming, by intensive mechanical stirring, of alkali activated slurries) followed by sintering at 1000°C. The full potential of recycled glass, however, has not been disclosed yet. The present investigation, infact, demonstrates that boro-alumino-silicate glass, from discarded pharmaceutical vials, may allow for sintering of cellular glass-ceramics at particularly low temperature, i.e. at 800°C. The full stabilisation of heavy metals from Plasmastone (already assessed for treatments at 1000° C) is not compromised, whereas the low processing temperatures favour the separation of magnetite, in turn imparting new functionalities (e.g. electromagnetic shielding) to wastederived glass-ceramic foams

Hindering NAT8L expression in hepatocellular carcinoma increases cytosolic aspartate delivery that fosters pentose phosphate pathway and purine biosynthesis promoting cell proliferation

N-acetylaspartate (NAA) is synthesized by the mitochondrial enzyme NAT8L, which uses acetyl-CoA and aspartate as substrates. These metabolites are fundamental for bioenergetics and anabolic requirements of highly proliferating cells, thus, NAT8L modulation may impinge on the metabolic reprogramming of cancer cells. Specifically, aspartate represents a limiting amino acid for nucleotide synthesis in cancer. Here, the expression of the NAT8L enzyme was modulated to verify how it impacts the metabolic adaptations and proliferative capacity of hepatocellular carcinoma. We demonstrated that NAT8L downregulation is asso-ciated with increased proliferation of hepatocellular carcinoma cells and immortalized hepatocytes. The over -expression of NAT8L instead decreased cell growth. The pro-tumoral effect of NAT8L silencing depended on glutamine oxidation and the rewiring of glucose metabolism. Mechanistically, NAT8L downregulation triggers aspartate outflow from mitochondria via the exporter SLC25A13 to promote glucose flux into the pentose phosphate pathway, boosting purine biosynthesis. These results were corroborated by the analyses of human and mouse hepatocellular carcinoma samples revealing a decrease in NAT8L expression compared to adjacent non -tumoral tissues. Overall, this work demonstrates that NAT8L expression in liver cells limits the cytosolic avail-ability of aspartate necessary for enhancing the pentose phosphate pathway and purine biosynthesis, counter-acting cell proliferation

Better Outcomes For Everybody (BOFE) evaluates the effectiveness and cost-effectiveness of a pharmacist-led intervention, delivered by community pharmacists in collaboration with physicians, in improving disease control, compared with usual care, in asthma and COPD patients during and after COVID-19: study protocol for a pragmatic, parallel randomised controlled trial

Introduction: In 2025, more than 400 million people will have asthma, and chronic obstructive pulmonary disease (COPD) will be the third leading cause of death by 2030. This trial, called better outcomes for everybody (BOFE), will evaluate the effectiveness and cost-effectiveness of a pharmacist-led intervention delivered by community pharmacists in collaboration with physicians to asthma and COPD patients to improve disease control compared with usual care. Methods: A pragmatic parallel 2-arm randomized controlled trial will be conducted in one Italian region (Sicily). A 2:1 randomization and sample size of 900 adult patients (450 with asthma, 450 with COPD) will be sufficient to detect a difference of 15% between the intervention and control groups using a dichotomized score (controlled versus non-controlled) of the Asthma Control Test (ACT) and the Clinical Chronic Obstructive Pulmonary Disease Questionnaire (CCQ) with a two tails, 99% power and 5% significance level. A hundred pharmacists will recruit 9 consecutive patients each and administer either ACT or CCQ according to the patients’ disease. Patients will be followed up for 12 months, and the pharmacists will meet their patients every three months. The control group will receive usual care, the intervention a bespoke, structured, and systematic consultation immediately after baseline and 6 months later. The primary outcomes are asthma and COPD control at baseline and 12 months. Secondary outcomes: risk of uncontrolled asthma and COPD, number of active ingredients, pharmaceutical care issues, adherence to medications, minimal clinically important differences in asthma and COPD, and a full health economic evaluation. The analysis will follow an intention-to-treat principle. Generalized estimating equations will be used to test the primary outcomes. Ethics approval was obtained. Discussion: This is the first study conducted in Italy to assess the effectiveness and cost�effectiveness of a pharmacist-led intervention in asthma and COPD patients at the same time. This research could introduce a new model of care that can be adapted to other chronic conditions in primary care settings. The results will be disseminated to service users and their families via media, healthcare professionals via professional training and meetings, and researchers via conferences and publications